Cangrelor’s Approval Prospects: FDA Reviewers Say Yes, Team Leader Says No
This article was originally published in The Pink Sheet Daily
Executive Summary
As The Medicines Co.’s anticlotting drug heads to the Cardiovascular and Renal Drugs Advisory Committee, questions about comparator dosing and timing and the severity of bleeding events will be on the agenda.